09:22 AM EDT, 03/24/2025 (MT Newswires) -- Tenaya Therapeutics ( TNYA ) said Monday that preclinical data for TN-201, its gene therapy candidate for myosin-binding protein C3-associated hypertrophic cardiomyopathy, showed improved heart function.

Published preclinical data also showed extended survival and lower cardiac biomarkers associated with fibrosis and heart failure, the company said.

A mouse surrogate of TN-201 was tested against vehicle in a model that mimics severe disease in humans, Tenaya said.

The company said the results, which were dose-dependent and lasted 20 months after treatment, support its clinical development plan for TN-201. Tenaya is conducting a phase 1b/2 clinical trial to assess TN-201 as a potential treatment for myosin-binding protein C3-associated hypertrophic cardiomyopathy.